Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 353

1.

Serum Concentrations of p-Cresyl Sulfate and Indoxyl Sulfate, but Not Inflammatory Markers, Increase in Incident Peritoneal Dialysis Patients in Parallel with Loss of Residual Renal Function.

Viaene L, Meijers BK, Vanrenterghem Y, Evenepoel P.

Perit Dial Int. 2015 Jul-Aug;35(4):492. doi: 10.3747/pdi.2015.00095. No abstract available.

2.

Time course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantation.

Claes KJ, Bammens B, Kuypers DR, Meijers B, Naesens M, Sprangers B, Vanrenterghem Y, Lerut E, de Loor H, Evenepoel P.

Nephrol Dial Transplant. 2014 Oct;29(10):1965-72. doi: 10.1093/ndt/gfu219. Epub 2014 Jun 23.

PMID:
24957811
3.

Postimplantation X-ray parameters predict functional catheter problems in peritoneal dialysis.

Bammens B, Peeters D, Jaekers J, Claes KJ, Evenepoel P, Kuypers D, Meijers B, Naesens M, Vanrenterghem Y, Monbaliu D.

Kidney Int. 2014 Nov;86(5):1001-6. doi: 10.1038/ki.2014.203. Epub 2014 Jun 18.

4.

Intrarenal resistive index after renal transplantation.

Naesens M, Heylen L, Lerut E, Claes K, De Wever L, Claus F, Oyen R, Kuypers D, Evenepoel P, Bammens B, Sprangers B, Meijers B, Pirenne J, Monbaliu D, de Jonge H, Metalidis C, De Vusser K, Vanrenterghem Y.

N Engl J Med. 2013 Nov 7;369(19):1797-806. doi: 10.1056/NEJMoa1301064.

5.

Serum concentrations of p-cresyl sulfate and indoxyl sulfate, but not inflammatory markers, increase in incident peritoneal dialysis patients in parallel with loss of residual renal function.

Viaene L, Meijers BK, Bammens B, Vanrenterghem Y, Evenepoel P.

Perit Dial Int. 2014 Jan-Feb;34(1):71-8. doi: 10.3747/pdi.2012.00276. Epub 2013 Oct 31. Erratum in: Perit Dial Int. 2015 Jul-Aug;35(4):492.

6.

Post-streptococcal glomerulonephritis: not an extinct disease!

Demuynck M, Lerut E, Kuypers D, Evenepoel P, Claes K, Naesens M, Meijers B, Vanrenterghem Y, Bammens B.

Acta Clin Belg. 2013 May-Jun;68(3):215-7.

PMID:
24156223
7.

Long-term exposure to belatacept in recipients of extended criteria donor kidneys.

Charpentier B, Medina Pestana JO, Del C Rial M, Rostaing L, Grinyó J, Vanrenterghem Y, Matas A, Zhang R, Mühlbacher F, Pupim L, Florman S.

Am J Transplant. 2013 Nov;13(11):2884-91. doi: 10.1111/ajt.12459. Epub 2013 Sep 18.

8.

Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism.

de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR.

Pharmacogenomics. 2013 Sep;14(12):1467-80. doi: 10.2217/pgs.13.133.

PMID:
24024898
9.

The predictive value of kidney allograft baseline biopsies for long-term graft survival.

De Vusser K, Lerut E, Kuypers D, Vanrenterghem Y, Jochmans I, Monbaliu D, Pirenne J, Naesens M.

J Am Soc Nephrol. 2013 Nov;24(11):1913-23. doi: 10.1681/ASN.2012111081. Epub 2013 Aug 15.

10.

Aortic calcifications and arterial stiffness as predictors of cardiovascular events in incident renal transplant recipients.

Claes KJ, Heye S, Bammens B, Kuypers DR, Meijers B, Naesens M, Vanrenterghem Y, Evenepoel P.

Transpl Int. 2013 Oct;26(10):973-81. doi: 10.1111/tri.12151. Epub 2013 Jul 19.

11.

Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD.

Poesen R, Viaene L, Verbeke K, Claes K, Bammens B, Sprangers B, Naesens M, Vanrenterghem Y, Kuypers D, Evenepoel P, Meijers B.

Clin J Am Soc Nephrol. 2013 Sep;8(9):1508-14. doi: 10.2215/CJN.00300113. Epub 2013 Jun 27.

12.

Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome.

Vanhove T, Kuypers D, Claes KJ, Evenepoel P, Meijers B, Naesens M, Vanrenterghem Y, Cornelis T, Bammens B.

Transpl Int. 2013 Aug;26(8):813-21. doi: 10.1111/tri.12133. Epub 2013 Jun 10.

13.

Combined kidney and intestinal transplantation in patients with enteric hyperoxaluria secondary to short bowel syndrome.

Ceulemans LJ, Nijs Y, Nuytens F, De Hertogh G, Claes K, Bammens B, Naesens M, Evenepoel P, Kuypers D, Vanrenterghem Y, Monbaliu D, Pirenne J.

Am J Transplant. 2013 Jul;13(7):1910-4. doi: 10.1111/ajt.12305. Epub 2013 Jun 3.

14.

Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring.

Kuypers DR, Peeters PC, Sennesael JJ, Kianda MN, Vrijens B, Kristanto P, Dobbels F, Vanrenterghem Y, Kanaan N; ADMIRAD Study Team.

Transplantation. 2013 Jan 27;95(2):333-40. doi: 10.1097/TP.0b013e3182725532.

PMID:
23263559
15.

Renal cell carcinoma in the allograft: what is the role of polyomavirus?

Neirynck V, Claes K, Naesens M, De Wever L, Pirenne J, Kuypers D, Vanrenterghem Y, Poppel HV, Kabanda A, Lerut E.

Case Rep Nephrol Urol. 2012 Jul;2(2):125-34. doi: 10.1159/000341917. Epub 2012 Sep 5.

16.

Chronic histological damage in early indication biopsies is an independent risk factor for late renal allograft failure.

Naesens M, Kuypers DR, De Vusser K, Vanrenterghem Y, Evenepoel P, Claes K, Bammens B, Meijers B, Lerut E.

Am J Transplant. 2013 Jan;13(1):86-99. doi: 10.1111/j.1600-6143.2012.04304.x. Epub 2012 Nov 8.

17.

In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.

de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR.

Clin Pharmacol Ther. 2012 Sep;92(3):366-75. doi: 10.1038/clpt.2012.109. Epub 2012 Aug 8.

PMID:
22871995
18.

A multicenter, randomized, double-blind study comparing different FK778 doses (manitimus) with tacrolimus and steroids vs. MMF with tacrolimus and steroids in renal transplantation.

Wlodarczyk Z, Vanrenterghem Y, Krämer BK, Squifflet JP, Ostrowski M.

BMC Nephrol. 2012 Jul 26;13:68. doi: 10.1186/1471-2369-13-68.

19.

Evidence in favor of a severely impaired net intestinal calcium absorption in patients with (early-stage) chronic kidney disease.

Viaene L, Meijers BK, Vanrenterghem Y, Evenepoel P.

Am J Nephrol. 2012;35(5):434-41. doi: 10.1159/000338299. Epub 2012 Apr 23.

PMID:
22538635
20.

Daytime rhythm and treatment-related fluctuations of serum phosphorus concentration in dialysis patients.

Viaene L, Meijers B, Vanrenterghem Y, Evenepoel P.

Am J Nephrol. 2012;35(3):242-8. doi: 10.1159/000336308. Epub 2012 Feb 18.

PMID:
22353750
21.

Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys.

Pestana JO, Grinyo JM, Vanrenterghem Y, Becker T, Campistol JM, Florman S, Garcia VD, Kamar N, Lang P, Manfro RC, Massari P, Rial MD, Schnitzler MA, Vitko S, Duan T, Block A, Harler MB, Durrbach A.

Am J Transplant. 2012 Mar;12(3):630-9. doi: 10.1111/j.1600-6143.2011.03914.x. Epub 2012 Feb 2.

22.

Impact of vascular calcification on corrected QT interval at the time of renal transplantation.

Claes KJ, Heye S, Nuyens D, Bammens B, Kuypers DR, Vanrenterghem Y, Evenepoel P.

Am J Nephrol. 2012;35(1):24-30. doi: 10.1159/000334597. Epub 2011 Dec 6.

PMID:
22143191
23.

Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients.

Viaene L, Bammens B, Meijers BK, Vanrenterghem Y, Vanderschueren D, Evenepoel P.

Nephrol Dial Transplant. 2012 May;27(5):2017-22. doi: 10.1093/ndt/gfr596. Epub 2011 Oct 24.

PMID:
22025115
24.

Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study.

Evenepoel P, Sprangers B, Lerut E, Bammens B, Claes K, Kuypers D, Meijers B, Vanrenterghem Y.

Clin Transplant. 2012 May-Jun;26(3):393-402. doi: 10.1111/j.1399-0012.2011.01524.x. Epub 2011 Oct 18.

PMID:
22007637
25.

Prevalence and determinants of anemia in the immediate postkidney transplant period.

Poesen R, Bammens B, Claes K, Kuypers D, Vanrenterghem Y, Monbaliu D, Evenepoel P.

Transpl Int. 2011 Dec;24(12):1208-15. doi: 10.1111/j.1432-2277.2011.01340.x. Epub 2011 Sep 19.

26.

FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study.

Hoitsma AJ, Woodle ES, Abramowicz D, Proot P, Vanrenterghem Y; FTY720 Phase II Transplant Study Group.

Nephrol Dial Transplant. 2011 Nov;26(11):3802-5. doi: 10.1093/ndt/gfr503. Epub 2011 Sep 12.

PMID:
21911597
27.

Reduction in protein-bound solutes unacceptable as marker of dialysis efficacy during alternate-night nocturnal hemodialysis.

Meijers B, Toussaint ND, Meyer T, Bammens B, Verbeke K, Vanrenterghem Y, Kerr PG, Evenepoel P.

Am J Nephrol. 2011;34(3):226-32. doi: 10.1159/000330176. Epub 2011 Jul 23.

PMID:
21791919
28.

In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.

de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR.

Clin Pharmacol Ther. 2011 Sep;90(3):414-22. doi: 10.1038/clpt.2011.130. Epub 2011 Jul 13.

PMID:
21753749
29.

Recurrence and graft loss after kidney transplantation for henoch-schonlein purpura nephritis: a multicenter analysis.

Kanaan N, Mourad G, Thervet E, Peeters P, Hourmant M, Vanrenterghem Y, De Meyer M, Mourad M, Maréchal C, Goffin E, Pirson Y.

Clin J Am Soc Nephrol. 2011 Jul;6(7):1768-72. doi: 10.2215/CJN.00520111.

30.

Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study.

Claes K, Meier-Kriesche HU, Schold JD, Vanrenterghem Y, Halloran PF, Ekberg H.

Nephrol Dial Transplant. 2012 Feb;27(2):850-7. doi: 10.1093/ndt/gfr238. Epub 2011 May 26.

PMID:
21617197
31.

Immunosuppression: does one regimen fit all?

Sprangers B, Kuypers DR, Vanrenterghem Y.

Transplantation. 2011 Aug 15;92(3):251-61. doi: 10.1097/TP.0b013e31822094d1. Review.

PMID:
21593703
32.

Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).

Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyó J, Neumayer HH, Lang P, Larsen CP, Mancilla-Urrea E, Pestana JM, Block A, Duan T, Glicklich A, Gujrathi S, Vincenti F.

Transplantation. 2011 May 15;91(9):976-83. doi: 10.1097/TP.0b013e31820c10eb.

PMID:
21372756
33.

A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1'-hydroxymidazolam and 4-hydroxymidazolam in human plasma.

de Loor H, de Jonge H, Verbeke K, Vanrenterghem Y, Kuypers DR.

Biomed Chromatogr. 2011 Oct;25(10):1091-8. doi: 10.1002/bmc.1576. Epub 2010 Dec 29.

PMID:
21204116
34.

A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients.

Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y.

Clin Ther. 2010 Nov;32(12):2012-23. doi: 10.1016/j.clinthera.2010.11.010.

PMID:
21118736
35.

An integrated safety profile analysis of belatacept in kidney transplant recipients.

Grinyó J, Charpentier B, Pestana JM, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, Apanovitch AM, Gujrathi S, Agarwal M, Thomas D, Larsen CP.

Transplantation. 2010 Dec 27;90(12):1521-7. doi: 10.1097/TP.0b013e3182007b95.

PMID:
21088650
36.

Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.

Larsen CP, Grinyó J, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Breshahan B, Campistol JM, Florman S, Rial Mdel C, Kamar N, Block A, Di Russo G, Lin CS, Garg P, Charpentier B.

Transplantation. 2010 Dec 27;90(12):1528-35. doi: 10.1097/TP.0b013e3181ff87cd.

PMID:
21076381
37.

Measuring total blood calcium displays a low sensitivity for the diagnosis of hypercalcemia in incident renal transplant recipients.

Evenepoel P, Bammens B, Claes K, Kuypers D, Meijers BK, Vanrenterghem Y.

Clin J Am Soc Nephrol. 2010 Nov;5(11):2085-92. doi: 10.2215/CJN.02460310. Epub 2010 Sep 9.

38.

Five-year safety and efficacy of belatacept in renal transplantation.

Vincenti F, Blancho G, Durrbach A, Friend P, Grinyo J, Halloran PF, Klempnauer J, Lang P, Larsen CP, Mühlbacher F, Nashan B, Soulillou JP, Vanrenterghem Y, Wekerle T, Agarwal M, Gujrathi S, Shen J, Shi R, Townsend R, Charpentier B.

J Am Soc Nephrol. 2010 Sep;21(9):1587-96. doi: 10.1681/ASN.2009111109. Epub 2010 Jul 15.

39.

Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation.

de Jonge H, Kuypers DR, Verbeke K, Vanrenterghem Y.

Transplantation. 2010 Sep 15;90(5):523-9. doi: 10.1097/TP.0b013e3181e9feda.

PMID:
20592652
40.

Pediatric organ allocation: matching tissue and needs.

Sprangers B, Vanrenterghem Y.

Transplantation. 2010 Aug 15;90(3):244-5. doi: 10.1097/TP.0b013e3181e46a3e. No abstract available.

PMID:
20555309
41.

Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: the need for true drug exposure measurements.

Kuypers DR, Bammens B, Claes K, Evenepoel P, Vanrenterghem Y.

Transplantation. 2010 May 27;89(10):1296-7; author reply 1297-8. doi: 10.1097/TP.0b013e3181d84c66. No abstract available.

PMID:
20555228
42.

Steroid avoidance or withdrawal after kidney transplantation: a balancing act.

Sprangers B, Vanrenterghem Y.

Transplantation. 2010 Aug 27;90(4):350-2. doi: 10.1097/TP.0b013e3181e5927a. No abstract available.

PMID:
20548264
43.

Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.

Kuypers DR, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y.

Ther Drug Monit. 2010 Aug;32(4):394-404. doi: 10.1097/FTD.0b013e3181e06818.

PMID:
20526235
44.

Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.

Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D, Vanderschueren D, Vanrenterghem Y.

Clin J Am Soc Nephrol. 2010 Jul;5(7):1268-76. doi: 10.2215/CJN.08241109. Epub 2010 May 6.

45.

p-Cresol and cardiovascular risk in mild-to-moderate kidney disease.

Meijers BK, Claes K, Bammens B, de Loor H, Viaene L, Verbeke K, Kuypers D, Vanrenterghem Y, Evenepoel P.

Clin J Am Soc Nephrol. 2010 Jul;5(7):1182-9. doi: 10.2215/CJN.07971109. Epub 2010 Apr 29.

46.

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, Lin CS, Garg P, Larsen CP.

Am J Transplant. 2010 Mar;10(3):535-46. doi: 10.1111/j.1600-6143.2009.03005.x.

47.

Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids.

Glotz D, Charpentier B, Abramovicz D, Lang P, Rostaing L, Rifle G, Vanrenterghem Y, Berthoux F, Bourbigot B, Delahousse M, Chalopin JM, Cassuto E, Lefrançois N.

Transplantation. 2010 Jun 27;89(12):1511-7. doi: 10.1097/TP.0b013e3181db09e4.

PMID:
20386144
48.

Return to work and social participation: does type of organ transplantation matter?

De Baere C, Delva D, Kloeck A, Remans K, Vanrenterghem Y, Verleden G, Vanhaecke J, Nevens F, Dobbels F.

Transplantation. 2010 Apr 27;89(8):1009-15. doi: 10.1097/TP.0b013e3181ce77e5.

PMID:
20147883
49.

Troponin I is a predictor of acute cardiac events in the immediate postoperative renal transplant period.

Claes K, Bammens B, Evenepoel P, Kuypers D, Coosemans W, Darius T, Monbaliu D, Pirenne J, Vanrenterghem Y.

Transplantation. 2010 Feb 15;89(3):341-6. doi: 10.1097/TP.0b013e3181bc405e.

PMID:
20145526
50.

Comparison of perceived health status among solid organ transplant candidates.

Dobbels F, Wernli-Fluri C, Denhaerynck K, Dickenmann M, Vanrenterghem Y, Dupont L, Nevens F, Vanhaecke J, De Geest S.

Clin Transplant. 2010 Sep-Oct;24(5):660-8. doi: 10.1111/j.1399-0012.2009.01163.x.

PMID:
19925463

Supplemental Content

Loading ...
Support Center